Tuesday, May 31, 2016

Roth ups Titan Pharma price target to $10

Roth ups Titan Pharma price target to $10

May 30, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to $10 from $7.75 after the FDA approved Titan’s six-month Probuphine implant for the treatment of opioid addiction. The stock closed at $7.07 on Friday. “The hook here is forced compliance,” writes analyst Scott Henry. “The implant removes the risk of noncompliant […]

FDA approves Titan’s Probuphine implant for opioid dependence

FDA approves Titan’s Probuphine implant for opioid dependence

May 26, 2016 by · Leave a Comment 

http://www.youtube.com/watch?v=g9e-i9Idjrw’]

Tweet The FDA has approved Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine. “Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to make […]

Roth resumes coverage of Fibrocell at buy

Roth resumes coverage of Fibrocell at buy

May 24, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and $7 price target. The stock closed at $2.12 on Monday. Fibrocell leverages its expertise with fibroblasts to target diseases of the skin, connective tissue and joints. The technology can take advantage of the inherent properties of fibroblasts, but also […]

Roth adjusts DelMar Pharma price target to $12

Roth adjusts DelMar Pharma price target to $12

May 23, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has adjusted its price target for DelMar Pharmaceuticals (OTCQX:DMPID) to $12 from $3 after the company’s 1-for-4 reverse stock split. The stock closed at $5.41 on Friday. Analyst Joseph Pantginis writes that the company’s net equity and operating funds are now sufficient to meet the goal of up listing to a […]

Anavex gets orphan drug status in Rett syndrome

Anavex gets orphan drug status in Rett syndrome

May 20, 2016 by · Leave a Comment 

Tweet The FDA has granted orphan drug designation to Anavex Life Sciences’ (NASDAQ:AVXL) ANAVEX 2-73 for the treatment of Rett syndrome. In a statement, Christopher Missling, president and CEO, said orphan drug designation marks the first U.S. movement for ANAVEX 2-73. Rett syndrome is a devastating disease occurring in early childhood and almost exclusively in […]

Roth ups Celator Pharma price target to $26

Roth ups Celator Pharma price target to $26

May 19, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for Celator Pharmaceuticals (NASDAQ:CPXX) to $26 from $22, after the company’s Vyxeos drug candidate received breakthrough therapy designation from the FDA. The stock closed at $15.07 on Wednesday “This is an important next step for Vyxeos on the path to what we believe is likely approval,” […]

FDA grants Profound Medical IDE approval for TULSA-PRO

FDA grants Profound Medical IDE approval for TULSA-PRO

May 19, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) has received investigational device exemption (IDE) approval from the FDA for a multicenter pivotal clinical trial to evaluate the efficacy of the TULSA-PRO System in patients with localized prostate cancer. TULSA-PRO, which has received CE Mark in Europe, combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop thermal feedback control, providing […]

ARIAD hopes to launch second oncology drug in early 2017

ARIAD hopes to launch second oncology drug in early 2017

May 17, 2016 by · Leave a Comment 

Tweet ARIAD Pharmaceuticals (NASDAQ:ARIA) is hoping to receive FDA approval to commercialize in early 2017 its second orphan oncology product, brigatinib, for the treatment of certain genetic forms of non-small cell lung cancer. At the end of 2012, the company launched Iclusig (ponatinib) to treat patients with several genetic types of chronic myeloid leukemia. “As […]

Dipexium completes enrollment in second Phase 3 trial

Dipexium completes enrollment in second Phase 3 trial

May 16, 2016 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed patient enrollment  in the OneStep-1 pivotal Phase 3 clinical trial of its Locilex broad-spectrum, topical antibiotic peptide. Last week, the company reached the enrollment objective in the OneStep-2 pivotal trial. OneStep-1 and OneStep-2 are identical, Phase 3 clinical trials conducted under a special protocol assessment with the FDA to […]

Dipexium completes enrollment in one Locilex Phase 3 trial

Dipexium completes enrollment in one Locilex Phase 3 trial

May 12, 2016 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed the patient enrollment objective in the OneStep-2 Phase 3 clinical trial of its Locilex topical antibiotic peptide. The company’s OneStep-1 Phase 3 clinical trial has passed the 98% enrollment mark and is expected to reach the 180-patient enrollment objective soon. OneStep-1 and OneStep-2 are identical, Phase 3 clinical trials […]

Next Page »

Email Newsletters with Constant Contact
Google+